TruScreen Group Ltd (NZX/ASX: TRU) is a medtech company that is commercialising the TRU system.

TruScreen Group Ltd (NZX: TRU) provides an opto-electrical technology-based real-time, low cost and portable system for the detection of cancer or pre-cancerous cells in cervical tissues.

Truscreen Group Limited is pleased to advise that the leading private medical services provider , Dr. Sulaiman Al-Habib Medical Group, has recently completed the analysis of results from its cervical screening clinical evaluation of TruScreen Ultra and Liquid Based Cytology (LBC).

Truscreen Group Limited is pleased to advise that its China distributor has placed an order for 40 TruScreen cervical cancer screening devices for installation into China’s growing public Health Check Sector. Delivery is expected in April 2023.

Truscreen Group Limited is pleased to advise that further to the announcement of 17 February 2023 “Truscreen to lodge a pro rata renounceable rights issue”, the Company has received firm commitments from a number of investors for an initial Placement of 20,000,000 shares at NZ$0.03 each to raise $600,000, before costs.

Truscreen Group Limited announced its intention to launch a 1 for 5 pro-rata renounceable rights issue to raise up to circa $2.2 million ("Rights Offer”) on 17 February 2023.

Further to the announcement on 17 February 2023 in relation to a Pro Rata Renounceable Rights Issue, TruScreen is pleased to provide the Offer Document, attached to this announcement.

Notice of Offer of Same Class Financial Products for Issue. Truscreen Group Limited intends to undertake an offer of new ordinary shares in TRU by way of a pro-rata 1 for 5 renounceable rights offer to eligible shareholders followed by an Oversubscription Bookbuild Facility process.

A Corporate Action Notice relating to a Pro Rata Renounceable Rights Issue is attached.

TruScreen Group Limited is pleased to announce its intention to launch a one (1) for five (5) pro-rata renounceable rights issue to raise up to circa NZD$2.2 million ("Rights Offer”).

Cervical cancer screening technology company, TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company), is pleased to provide this commercial update.

Cervical cancer screening technology company, TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company), is pleased to provide this update on Distributor progress in November/ December 2022.

Template Results announcement - for Equity Security issuer/Equity and Debt Security issuer

Cervical cancer screening technology company, TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company), is pleased to provide its unaudited financial results for the six months to 30 September 2022 (1H FY23), along with the following operational update. TruScreen reports according to the New Zealand financial year, which runs from 1 April to 31 March.

Cervical cancer screening technology company, TruScreen Group Limited (NZX/ASX: TRU), is pleased to provide this market update which includes commentary on its unaudited financial results for the six months to 30 September 2022 (1H FY23).

Truscreen Limited is pleased to provide a copy of its November 2022 Stakeholders Newsletter. This gives an updated on TruScreen's performance and highlights key initiatives underway.

Truscreen Group Limited (NZX/ASX:TRU) is pleased to announce successful completion of the first global virtual medical symposium to key opinion leaders from 7 countries, on cervical cancer screening.

Truscreen Group Limited (NZX/ASX:TRU) is pleased to announce the appointment of Dr. Beata Edling as Chief Executive Officer.

TruScreen Group Limited (NZX/ASX: TRU) is pleased to announce that it has executed a five-year manufacturing contract with its current critical supplier, Zapco International Limited, for the manufacture and supply of Single Use Sensors.

TruScreen Group Limited (NZX/ASX: TRU) is pleased to announce that its China distributor Beijing Siweixiangtai Technology Company Ltd (SWXT) has relaunched distribution of TruScreen cervical cancer screening device to Xinjiang Uygur Autonomous Region.

TruScreen Group Limited (NZX/ASX: TRU) is pleased to announce the establishment of a TruScreen-based cervical cancer screening centre in a new clinic in Cludad de Mexico (Mexico City) operated by leading healthcare provider Mexpharm Medical Clinical.

COGA Trial screened 15,661 women across 64 hospitals in 9 provinces over 3 years. TruScreen specificity surpassed Liquid Based Cytology (LBC) and hrHPV. TruScreen was determined to be a simple, effective and rapid real-time cervical cancer screening method

TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company’) is pleased to provide the following market update, outlining the Company’s progress.